Saint Louis, Missouri 63110


Purpose:

This project will collect quantitative pilot data that will allow the characterization of uptake and binding of 18F-AV-1451 (also known as F 18 T807), a novel tau imaging compound, in individuals with and without brain tau fibrils. The primary goal is to develop tau imaging technique as an antecedent biomarker of cognitive decline. The investigators propose to obtain preliminary data that will support the possibility of detecting cognitive decline in its earliest stages, before the occurrence of dementia.


Criteria:

Inclusion Criteria: 1. Male or female participants, at least 18 years of age. 2. Cognitively normal, or with mild dementia, as assessed clinically 3. Participant is able and willing to undergo testing (MRI or CT, PET, radioactive tracer injection, LP; for those unable to undergo an MRI, CT will be used to generate regions-of-interest). 4. Pre-menopausal women will undergo a urine pregnancy test within 24 hours of drug administration. Exclusion Criteria: 1. Has any condition that, in the Investigator's opinion, could increase risk to the participant, limit the participant's ability to tolerate the experimental procedures, or interfere with the collection/analysis of the data (for example, participants with severe chronic back pain might not be able to lie still during the scanning procedures). 2. Is deemed likely unable to perform the imaging procedures for any reason. 3. Has a high risk for Torsades de Pointes or is taking medications known to prolong QT interval. 4. Has hypersensitivity to F 18 T807 or any of its excipients. 5. Contraindications to PET, PET-CT or MR (e.g. electronic medical devices, inability to lie still for long periods) that make it unsafe for the individual to participate. 6. Severe claustrophobia. 7. Currently pregnant or breast-feeding. 8. For those electing to undergo the optional lumbar puncture: currently on anticoagulant of any form -


NCT ID:

NCT02414347


Primary Contact:

Principal Investigator
Tammie Benzinger, MD, PhD
Washington University School of Medicine

Kelley Jackson, BA
Phone: 314 362 6737
Email: jacksonk@mir.wustl.edu


Backup Contact:

N/A


Location Contact:

Saint Louis, Missouri 63110
United States

Kelley Jackson
Phone: 314-362-6737
Email: jacksonk@wustl.edu

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: November 24, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.